Comparison of Ion Personal Genome Machine Platforms for the Detection of Variants in BRCA1 and BRCA2
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Transition to next generation sequencing (NGS) for BRCA1/BRCA2 analysis in clinical laboratories is ongoing but different platforms and/or data analysis pipelines give different results resulting in difficulties in implementation. We have evaluated the Ion Personal Genome Machine (PGM) Platforms (Ion PGM, Ion PGM Dx, Thermo Fisher Scientific) for the analysis of BRCA1/2. Materials and Methods The results of Ion PGM with OTG-snpcaller, a pipeline based on Torrent mapping alignment program and Genome Analysis Toolkit, from 75 clinical samples and 14 reference DNA samples were compared with Sanger sequencing for BRCA1/BRCA2. Ten clinical samples and 14 reference DNA samples were additionally sequenced by Ion PGM Dx with Torrent Suite. Results Fifty types of variants including 18 pathogenic or variants of unknown significance were identified from 75 clinical samples and known variants of the reference samples were confirmed by Sanger sequencing and/or NGS. One false-negative results were present for Ion PGM/OTG-snpcaller for an indel variant misidentified as a single nucleotide variant. However, eight discordant results were present for Ion PGM Dx/Torrent Suite with both falsepositive and -negative results. A 40-bp deletion, a 4-bp deletion and a 1-bp deletion variant was not called and a false-positive deletion was identified. Four other variants were misidentified as another variant. Conclusion Ion PGM/OTG-snpcaller showed acceptable performance with good concordance with Sanger sequencing. However, Ion PGM Dx/Torrent Suite showed many discrepant results not suitable for use in a clinical laboratory, requiring further optimization of the data analysis for calling variants.
Abstract
Purpose Transition to next generation sequencing (NGS) for BRCA1/BRCA2 analysis in clinical laboratories is ongoing but different platforms and/or data analysis pipelines give different results resulting in difficulties in implementation. We have evaluated the Ion Personal Genome Machine (PGM) Platforms (Ion PGM, Ion PGM Dx, Thermo Fisher Scientific) for the analysis of BRCA1/2. Materials and Methods The results of Ion PGM with OTG-snpcaller, a pipeline based on Torrent mapping alignment program and Genome Analysis Toolkit, from 75 clinical samples and 14 reference DNA samples were compared with Sanger sequencing for BRCA1/BRCA2. Ten clinical samples and 14 reference DNA samples were additionally sequenced by Ion PGM Dx with Torrent Suite. Results Fifty types of variants including 18 pathogenic or variants of unknown significance were identified from 75 clinical samples and known variants of the reference samples were confirmed by Sanger sequencing and/or NGS. One false-negative results were present for Ion PGM/OTG-snpcaller for an indel variant misidentified as a single nucleotide variant. However, eight discordant results were present for Ion PGM Dx/Torrent Suite with both falsepositive and -negative results. A 40-bp deletion, a 4-bp deletion and a 1-bp deletion variant was not called and a false-positive deletion was identified. Four other variants were misidentified as another variant. Conclusion Ion PGM/OTG-snpcaller showed acceptable performance with good concordance with Sanger sequencing. However, Ion PGM Dx/Torrent Suite showed many discrepant results not suitable for use in a clinical laboratory, requiring further optimization of the data analysis for calling variants.
참고문헌 (27)
- Ford D, "Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium", Am J Hum Genet, 62, pp.676~689 (1998)[DOI]
- King MC, "Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2", Science, 302, pp.643~646 (2003)[DOI]
- Hartmann LC, "The role of risk-reducing surgery in hereditary breast and ovarian cancer", N Engl J Med, 374, pp.454~468 (2016)[DOI]
- or ovarian cancer genetic assessment, "NCCN guidelines, version 2. 2016. Breast and", pp.2016, National Comprehensive Cancer Network
- Tafe LJ, "Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys", Genet Med, 17, pp.58~62 (2015)[DOI]
- Gerhardus A, "Diagnostic accuracy of methods for the detection of BRCA1 and BRCA2 mutations: a systematic review", Eur J Hum Genet, 15, pp.619~627 (2007)[DOI]
- Chan M, "Development of a next-generation sequencing method for BRCA mutation screening: a comparison between a high-throughput and a benchtop platform", J Mol Diagn, 14, pp.602~612 (2012)[DOI]
- Feliubadalo L, "Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes", Eur J Hum Genet, 21, pp.864~870 (2013)[DOI]
- Judkins T, "Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk", BMC Cancer, 15, pp.215~ (2015)[DOI]
- De Leeneer K, "Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations", Hum Mutat, 32, pp.335~344 (2011)[DOI]
- Bosdet IE, "A clinically validated diagnostic second-generation sequencing assay for detection of hereditary BRCA1 and BRCA2 mutations", J Mol Diagn, 15, pp.796~809 (2013)[DOI]
- Tarabeux J, "Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model", Eur J Hum Genet, 22, pp.535~541 (2014)[DOI]
- Dacheva D, "Validation of an NGS approach for diagnostic BRCA1", BRCA2 mutation testing, 2015, pp.19, 119~130
- Kluska A, "New recurrent BRCA1", 2 mutations in Polish patients with familial breast, BMC Med Genomics, pp.2015, 8[DOI]
- Trujillano D, "Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and", or ovarian cancer, 2015, pp.17, 162~170
- 박준홍, "Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening", Annals of Laboratory Medicine, 36(2), pp.197~201 (2016), 대한진단검사의학회
- Strom CM, "Development and validation of a next-generation sequencing assay for BRCA1 and BRCA2 variants for the clinical laboratory", PLoS One, 10, pp.e0136419~ (2015)[DOI]
- Yeo ZX, "Improving indel detection specificity of the Ion Torrent PGM benchtop sequencer", PLoS One, 7, pp.e45798~ (2012)[DOI]
- Bragg LM, "Shining a light on dark sequencing: characterising errors in Ion Torrent PGM data", PLoS Comput Biol, 9, pp.e1003031~ (2013)[DOI]
- McKenna A, "The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data", Genome Res, 20, pp.1297~1303 (2010)[DOI]
- Zhu P, "OTG-snpcaller: an optimized pipeline based on TMAP and GATK for SNP calling from ion torrent data", PLoS One, 9, pp.e97507~ (2014)[DOI]
- Robinson JT, "Integrative genomics viewer", Nat Biotechnol, 29, pp.24~26 (2011)[DOI]
- Quail MA, "A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers", BMC Genomics, 13, pp.341~ (2012)[DOI]
- Enyedi MZ, "Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples", Oncotarget, 7, pp.61845~61859 (2016)
- Lincoln SE, "A systematic comparison of traditional and multigene panel testing for hereditary breast and ovarian cancer genes in more than 1000 patients", J Mol Diagn, 17, pp.533~544 (2015)[DOI]
- Yeo ZX, "Evaluation and optimisation of indel detection workflows for ion torrent sequencing of the BRCA1 and BRCA2 genes", BMC Genomics, 15, pp.516~ (2014)[DOI]
- Kang HP, "Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing", PeerJ, 4, pp.e2162~ (2016)[DOI]